<DOC>
	<DOCNO>NCT01874587</DOCNO>
	<brief_summary>The Phase III study include 174 patient locally advance oropharynx carcinoma , receive arc-IMRT ( Intensity-Modulated Radiation Therapy ) ( 70 Gy ) concomitant systemic therapy . Two arc-IMRT treatment arm compare : one `` standard '' arm base use single pre-treatment plan one `` experimental '' arm ( adaptive RT ) base weekly replanning spare salivary gland . The main objective increase 25 % salivary flow ( Parafilm ) 12 month RT thanks adaptive RT , decrease local control . The secondary objective increase salivary flow ( scintigraphy ) , reduce xerostomia , acute late toxicity ( Eisbruch questionnaire , MDAS-HN , v.4 CTCAE ) , maintain local control ( stop rule trial difference &gt; 15 % ) . 174 patient include 6 French center 2 year follow 2 year . The HPV ( Human Papillomavirus ) status identify tumor freeze . A central IMRT QA ( Quality Assurance ) perform .</brief_summary>
	<brief_title>Adaptative Radiotherapy Decrease Xerostomia Oropharynx Carcinoma</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Xerostomia</mesh_term>
	<mesh_term>Oropharyngeal Neoplasms</mesh_term>
	<criteria>1 . Locally advanced nonmetastatic carcinoma oropharynx limit T3 T4 ( whatever N ) N2N3 ( whatever T ) ( AJCC stage IIIIV ) 2 . Age ≥ 18 year ≤ 75 year 3 . Performance status ( WHO ≤ 2 ) 4 . Renal , hepatic cardiovascular function allow systemic treatment administration 5 . Adapted stomatologic care 6 . Signed informed consent form 7 . Membership beneficiary national insurance scheme 1 . Both parotids totally include target volume 2 . Stages T1 T2 positive node disease N1 3 . Neoadjuvant chemotherapy 4 . Exereses primitive tumor and/or node 5 . History cancer within 5 year ( except basocellular epithelioma cervical ) 6 . Previous neck radiotherapy 7 . Platinum salt , 5FluoroUracile ( 5FU ) agent cetuximab chemotherapy consideration 8 . Unstable disease ( cardiovascular , renal , pulmonary , systemic lupus sclerodermia ) incompatible study participation 9 . Patient participate therapeutic trial experimental drug , 30 day inclusion . 10 . Patient already recruit another biomedical research ( non interventional study authorize ) 11 . Pregnant breast feeding patient 12 . Patient deprive liberty , tutorship , guardianship place judicial protection 13 . Patient deem incapable give informed consent 14 . Patients , family , social , geographic psychological reason , adequately follow and/or incapable undergo regular control .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>Adaptative radiotherapy</keyword>
	<keyword>oropharynx carcinoma</keyword>
	<keyword>xerostomia</keyword>
</DOC>